PMID- 38404967
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240227
IS  - 1970-5565 (Print)
IS  - 1970-5557 (Electronic)
IS  - 1970-5557 (Linking)
VI  - 18
DP  - 2024
TI  - Management of Neuroendocrine Breast Carcinoma (NEBC): Review of Literature.
PG  - 12114
LID - 10.3389/or.2024.12114 [doi]
LID - 12114
AB  - Extra pulmonary high-grade poorly differentiated neuroendocrine carcinomas 
      (EP-NECs) are rare tumors that usually arise in the gastrointestinal and 
      genitourinary tracts. Primary neuroendocrine carcinoma of the breast (NEBC) is 
      extremely rare, representing less than 0.1% of all breast cancers and less than 
      1% of neuroendocrine neoplasms. Consequently, they can be misdiagnosed as other 
      types of breast cancer, however, proper immunohistochemical (IHC) studies can 
      assist with making the correct diagnosis. Management of NEBC can be challenging 
      given the paucity of evidence-based literature and should not routinely follow 
      the therapeutic guidelines of other breast cancers. In this article, we review 
      the current literature regarding the management of NEBC.
CI  - Copyright (c) 2024 Mohamed, Zeidalkilani, Asa, Trybula and Montero.
FAU - Mohamed, A
AU  - Mohamed A
AD  - Division of Hematology and Medical Oncology, University Hospitals Seidman Cancer 
      Center, Cleveland, OH, United States.
FAU - Zeidalkilani, J
AU  - Zeidalkilani J
AD  - Department of Medicine, University Hospitals Seidman Cancer Center, Cleveland, 
      OH, United States.
FAU - Asa, S L
AU  - Asa SL
AD  - Department of Pathology, University Hospitals Seidman Cancer Center, Case 
      Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, 
      United States.
FAU - Trybula, M
AU  - Trybula M
AD  - Division of Hematology and Medical Oncology, University Hospitals Seidman Cancer 
      Center, Cleveland, OH, United States.
FAU - Montero, Alberto J
AU  - Montero AJ
AD  - Division of Hematology and Medical Oncology, University Hospitals Seidman Cancer 
      Center, Cleveland, OH, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240209
PL  - Switzerland
TA  - Oncol Rev
JT  - Oncology reviews
JID - 101519906
PMC - PMC10884130
OTO - NOTNLM
OT  - breast
OT  - carcinoma
OT  - management
OT  - neuroendocrine
OT  - review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/02/26 06:43
MHDA- 2024/02/26 06:44
PMCR- 2024/02/09
CRDT- 2024/02/26 04:35
PHST- 2023/09/25 00:00 [received]
PHST- 2024/01/15 00:00 [accepted]
PHST- 2024/02/26 06:44 [medline]
PHST- 2024/02/26 06:43 [pubmed]
PHST- 2024/02/26 04:35 [entrez]
PHST- 2024/02/09 00:00 [pmc-release]
AID - 12114 [pii]
AID - 10.3389/or.2024.12114 [doi]
PST - epublish
SO  - Oncol Rev. 2024 Feb 9;18:12114. doi: 10.3389/or.2024.12114. eCollection 2024.